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1. Introduction 
The protein alpha-lactalbumin (α-LA) is present in the milk of nearly all mammals. Here it 
has a well-described function of controlling the specificity of a galatosyltransferase towards 
the formation of lactose, the common sugar present in milk. In recent years an entirely 
different activity has been associated with the protein. By forming a complex with oleic acid 
(OA) it shows cytotoxic activity against cells with an apparent selectivity for cancer cells. 
The complex is called HAMLET (Human α-lactalbumin Made LEthal to Tumor cells) and 
was originally discovered by serendipity. The complex was revealed during studies of the 
effect of anti-adhesive molecules from human milk on bacterial attachment to alveolar lung 
carcinoma cells [1]. A casein fraction, obtained after low pH precipitation of human milk at 
pH 4.3, was shown to exhibite cytotoxic activity. The dying cells displayed changes in 
morphology, cytoplasmic blebbing, nuclear condensation, and formed apoptotic bodies, 
comparable to cells that undergo classical apoptosis [2]. The tumoricidal component of the 
casein was retained in a DEAE-Trisacryl M column upon ion exchange chromatography, but 
eluted at high salt concentration (1M).  
The active component was identified as multimeric α-LA (MAL) by its oligomeric 
appearance in SDS-PAGE analysis with bands at 14, 28, and 100 kDa and was subsequently 
confirmed by Edman degradation and mass spectrometry [1,3]. The MAL was shown to 
contain a molten globule-like structure and cause apoptosis-induction in a variety of 
transformed and immature cells, but not in healthy differentiated cells [1,2,4]. The affected 
cells were carcinomas of lung, kidney, throat, bladder, colon, ovaries and the prostate, 
glioblastomas in the brain, melanomas, and leukemias. In contrast, native monomeric α-LA 
isolated from human whey showed no apoptosis-inducing activity. 
The difference in cytotoxic activity between the native-state α-LA and α-LA in MAL was not 
a consequence of post-translational modifications, but rather a conformational change 
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altering the tertiary structure while leaving the secondary structure intact, resulting in the 
partial unfolding and molten globule-like conformation of the protein in MAL [3]. 
The link between the altered folding of α-LA and apoptosis induction was subsequently 
identified by deliberate in vitro conversion of apo-state α-LA deprived of Ca2+, to an 
apoptosis-inducing complex on an anion-exchange chromatography column previously 
exposed to human milk casein [5]. Additional studies showed the requirement of a lipid 
cofactor in the stabilization of the partially unfolded state of α-LA, by the finding that α-LA 
in the complex was preserved in a molten globule-like conformation even at physiological 
pH and in the presence of Ca2+ at 25-37°C [2]. The lipid cofactor was identified as oleic acid 
(C18:1 cis Δ9) by chemical extraction of casein-conditioned column matrices and GC-MS 
analysis [5,6]. The name MAL was subsequently changed to HAMLET. A similar complex 
with bovine α-lactalbumin has been called BAMLET. 
2. Structure of α-LA 
Human α-LA is an acidic globular protein composed of 123 amino acids with a molecular 
mass of 14.2 kDa and homologous with the lysozyme protein family. It is secreted by the 
epithelia cells of the mammary gland during lactation, and this is the only tissue which 
expresses the protein [7-9]. The crystal structure of human and bovine α-LA has been 
resolved by X-ray crystallography [10,11]. The protein consists of two domains, a large one 
composed mainly of α-helical structures and a smaller β-sheet domain. The overall three 
dimensional structure is stabilized by a Ca2+ binding loop [12,13] (Figure 1). 
The large domain contains four α-helixes corresponding to amino acids 5-11 (A, dark blue), 
23-34 (B, light blue), 86-98 (C, yellow) and 105-109 (D, orange) and three short 310-helical 
domains corresponding to amino acids 12-16, 101-104 and 115-119. The smaller β-sheet 
domain contains a triple-stranded antiparallel β-sheet (amino acids 40-50, green) and a short 
310-helical domain (amino acids 76-82) [14]. The two domains are connected through a 
cysteine bridge (amino acids 73,91) creating the Ca2+ binding loop region. Additionally, two 
cysteine bridges are located in the α-helical structures (amino acids 6,120 and 28,111) and 
finally one bridge in the β-sheet domain (amino acids 61,77), aiding in the stabilization of 
the native conformation of α-LA [10,12]. The binding of Ca2+ to α-LA is required for correct 
formation of the disulfide bonds during protein folding [15]. 
3. Calcium-binding properties of α-LA 
The native human α-LA is a metalloprotein containing a high-affinity primary Ca2+ binding 
site and Ca2+-binding is required for the stabilization and structural integrity of the native 
fold [13,16-19]. The strong Ca2+ binding site, with an apparent association constant of 3 × 108 
M-1 at 20°C, is located in a loop between the two domains, and is coordinated by the side 
chain carboxylates of Asp82, Asp87, Asp88 and carbonyl oxygens of Lys79 and Asp84 
[10,20,21]. In Figure 1 only the side chains Asp82, Asp87 and Asp88 are shown. 
Furthermore, two water molecules also participate in the coordination of Ca2+ at the site, 
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creating a distorted pentagonal bipyramidal structure [10-13]. A secondary surface-located 
and low-affinity Ca2+ binding site was discovered by X-ray crystallography, which only 
binds Ca2+ at high concentrations. However, this binding site is believed to play no 
structural role in human α-LA [22]. 
 
Figure 1. Model of human α-lactalbumin drawn by PyMOL Molecular Graphics System, Version 1.5.0.1 
Schrödinger, LLC using the coordinates from [10]. The Ca2+ is shown as a ball in purple, helix A in dark 
blue, helix B in light blue, helix C in yellow, helix D in orange, while the β-sheet is in green. The sulfur 
atoms in the four disulfide bonds are indicated by small yellow balls.  
Other divalent cations, such as Mn2+, Mg2+, Na+ and K+ can also bind α-LA, competing with 
Ca2+ for the same binding site [13,23,24]. A distinct zinc binding site different from the 
calcium binding site has also been localized [25]. However, binding of these cations causes 
only minor structural changes and does not play a major structural role in α-LA, compared 
to the binding of Ca2+ [13]. 
The binding of Ca2+ to α-LA through re-normalization of the solvent Ca2+, temperature or pH 
conditions, and the release of Ca2+ through low pH, EDTA or heat treatment, have been 
shown in both circular dichroism spectroscopy and fluorescence spectroscopy data analysis, 
to cause structural and functional changes mainly in the tertiary structure, while leaving a 
native-like secondary structure [13,18,20,24,26]. The native folded Ca2+-bound α-LA has 
higher structural stability against increased temperatures, pressures or denaturant 
concentrations [13,24,27-30]. 
4. Biological function of α-LA 
Alpha-lactalbumin folding occurs in the lumen of the endoplasmatic reticulum and the 
protein is subsequently transported to the membrane surface of the Golgi apparatus, where 
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it interacts with galactosyltransferase creating the lactose synthase complex [13,31]. In the 
absence of α-lactalbumin, the enzyme is a non-specific galactosyltransferase involved in 
transferring galactosyl groups from UDP-galactose to a range of different substrates [13,31]. 
Alpha-lactalbumin functions as a substrate modifier, increasing specificity and affinity of 
the galactosyltransferase for glucose, when catalyzing the final step of lactose production in 
a lactating mammary gland [7,32]. 
5. Folding of α-LA 
A noteworthy property of α-LA is the ability of the protein to adopt relatively stable partially 
unfolded intermediates under various conditions. Accordingly, it has been intensely used as a 
protein folding model in many studies. The classical molten globule of α-LA was defined as the 
acid denatured compact state of α-LA at pH 2.0 with fluctuating tertiary structure [13,33,34]. 
However, α-LA can adopt molten globule-like states during Ca2+-free (apo-state) conditions, 
during high temperatures at 90°C and in the presence of denaturants [14,17,35,36]. Similar 
conformational states can also be formed by reduction of the disulfide bonds in α-LA [37,38]. 
The molten globule-like conformational states of α-LA are not significantly populated at 
physiological conditions [26]. In addition, stable unfolded states of α-LA only persist at low 
pH or in the absence of metal ions, since the protein instantly returns to the native 
conformation, if solution conditions are re-normalized [19]. In the molten globule 
conformation, α-LA has a native-like secondary structure, a less well-defined tertiary 
structure and a larger stokes radius compared to the native protein [14,34,39]. 
The apo-state of α-LA, a molten globular-like conformation, is required for the formation of 
HAMLET. This conformation has high instability and sensitivity towards the ionic strength 
of the solution, compared to the native state of the protein [19]. However, the apo-state α-
LA is more hydrophobic than the native state of the protein, rendering it prone to fatty acid 
binding [2]. The apo-state of α-LA is thus stabilized by binding to specific fatty acids in the 
HAMLET complex [6]. The proposed requirement of a special molten globular-like 
conformation of the proteinaceous component in HAMLET-like complexes has been 
challenged, as bovine β-lactoglobulin in complex with OA had cytotoxic activity exceeding 
that of HAMLET without retaining such a structure [40]. 
6. Fatty acid binding profile of α-LA 
Alpha-lactalbumin possesses several fatty acid binding sites, and has been shown to bind 
stearic acid, palmitic acid and oleic acid spin-labelled fatty acid analogs [6,41]. The release of 
the Ca2+ ion and subsequent unfolding of the protein triggers α-LA to achieve a new fatty 
acid binding profile, with a higher affinity for cis-unsaturated fatty acids than for the 
corresponding trans conformations. 
The interaction between apo-state α-LA and distinctive fatty acids has been studied, with 
the observation that certain fatty acids interact with apo-state α-LA in a stereo-specific 
manner [6]. Is has been found, that saturated C18 fatty acids, unsaturated C18:1 trans fatty 
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acids and fatty acids with longer or shorter carbon chains only form insignificant amounts 
of complexes with apo-state α-LA [6]. All unsaturated cis fatty acids are able to form stable 
complexes with apo-state α-LA, with oleic acid showing the highest conversion efficiency 
[6]. It was found, however, that only oleic acid (C18:1 cis Δ9 – in HAMLET) and vaccenic 
acid (C18:1 cis Δ11) in complex with apo-state α-LA showed biological activity in apoptosis 
assay, suggesting that unsaturated C18:1 cis fatty acids have the correct stereo-specificity to 
bind apo-state α-LA in the formation and stabilize the HAMLET complex [6]. Another study 
has found that vaccenic acid, palmitoleic acid linoleic acid had similar activity as oleic acid 
while elaidic acid and stearic acid shoved a weaker activity [42]. The fatty acid profile of α-
LA thus seems to be rather broad and not as specific as initially anticipated. 
Based on the three-dimensional structures of native and apo-state α-LA, two tentative 
hydrophobic regions and possible fatty acid binding sites within α-LA have been proposed. 
One is suggested in the interface between the two sub-domains including the C- and D-helix 
and the β-sheet domain [6,43,44]. The other is anticipated to be formed by residues within 
the A, B and 310-helices. 
The binding of oleic acid to bovine apo-state α-LA has previously been shown to induce 
changes in the secondary structure of the protein, resulting in a typical molten globule state 
of the protein [45]. Far-UV CD of oleic acid binding to human apo-state α-LA showed 
similar results, with an increase in α-helical structure, largely independent of the 
temperature conditions [30]. 
Upon Ca2+ release structural changes in α-LA also occur in the cleft between the two 
domains, with the slight expansion of the Ca2+-binding loop tilting the 310 helix toward the C 
helix, causing disruption of the aromatic cluster composed of Trp60, Trp104, Phe53 and 
Tyr103 in the interface between the two domains [11]. X-ray crystallography and NMR 
spectroscopy studies have revealed that apo-state bovine α-LA contains a largely intact α-
helical domain with native side chain packing and an unstructured β-sheet domain [11,46]. 
Similar findings have been made for the molten globule-like conformation of human apo-
state α-LA [47]. Therefore, it has been proposed that oleic acid binds in the area between the 
two domains, thus stabilizing the molten globule-like state of HAMLET and allowing Ca2+ 
binding without any effect on the tumoricidal activity [2,6]. Nevertheless, it is still unclear 
exactly how oleic acid binds to apo-state α-LA. Although the apo-state of α-LA is negatively 
charged, it may be hydrophobic interactions mediating the binding of the oleic acid, 
considering the increased hydrophobicity of apo-state α-LA compared to native α-LA 
[11,46,48,49]. Furthermore, even though the apo-state is negatively charged, it may also 
possess positively charged residues that are able to bind to the negatively charged polar 
head-groups of the oleic acids through electrostatic interactions [48,49]. Accordingly, it has 
been suggested that hydrophobic amino acids in the interface between the two domains 
may bind the fatty acid tail, while positively charged amino acids such as Arg70, Lys94 and 
Lys99 are plausible coordination residues for the fatty acid head group [2]. 
In contrast to these above-mentioned suggestions, one of the same studies showed that 
several proteolytically generated fragments of α-LA were able to incorporate oleic acid, 
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implying that there is not only one single fatty acid binding site in HAMLET [48]. The exact 
mechanism of fatty acid binding to α-LA remains uncertain. 
7. Structure of HAMLET 
HAMLET is defined as a conversion complex between apo-state α-LA and a C18:1 cis fatty 
acid co-factor, which has the ability to induce apoptosis selectively in tumor cells [6]. 
HAMLET has been described as the first discovered example of a protein that exhibits a 
well-defined function in the native structure, but additionally acquires a potentially 
beneficial function following partial unfolding [1,5,38]. 
Studies of the HAMLET structure by tryptophan fluorescence spectroscopy, near-UV CD 
spectroscopy and far-UV CD spectroscopy have revealed that the complex retains a stable, 
partially unfolded, molten globule-like conformation even at physiological conditions, in 
contrast to partially unfolded α-LA, which reverts to the native conformation, if solution 
conditions are re-normalized [3,5,14,19,29,45]. In this molten globule-like conformation, α-
LA in the HAMLET complex showed retention of the secondary structure, near-complete 
loss of the tertiary structure, a larger stokes radius, and increased exposure of hydrophobic 
surfaces, compared to native α-LA [3,5,14,34,39,50]. 
8. Characteristics of HAMLET 
The formation, stabilization and cytotoxic activity of the HAMLET complex have been 
shown to require both partial unfolding of α-LA and the binding of a fatty acid co-factor 
[5,6,19,51]. The partial unfolding of α-LA, e.g. through metal ion depletion, results in 
destabilization of the β-sheet domain, while leaving the α-helix domain largely unchanged, 
paving the way for fatty acid binding and subsequent HAMLET formation [19,50]. In 
accordance with this, it has been shown that the tumoricidal activity of HAMLET is largely 
independent of the β-sheet domain and C-terminal portion of human α-LA, since the 
isolated α-helix domain of α-LA was able to form a cytotoxic complex with OA [52]. 
Additional changes in the α-LA structure can induce the formation of HAMLET or 
HAMLET analogs. It has been proposed that the entire 123-residue sequence of α-LA is not 
required for cytotoxic activity, as fragments of α-LA in a complex with OA were able to 
induce apoptosis in Jurkat tumor cells [48]. Furthermore, it has been shown that a 
recombinant variant of human α-LA, where all cysteine residues were substituted with 
alanine residues, had the ability to form cytotoxic HAMLET complex analogs [38]. In 
addition, an α-LA mutant where Asp87 was shifted to an alanine with no Ca2+ binding 
activity was also able to form cytotoxic complexes with oleic acids, implying that a 
functional Ca2+ site is not required for the conversion of α-LA to the active complex or to 
cause cell death [19]. This being the case despite the fact that HAMLET has a high Ca2+-
affinity, with a Ca2+ association constant of 5.3×106 M-1 at physiological salt conditions [19]. 
However, the structural changes induced upon Ca2+ binding have no effect on the cytotoxic 
activity of the complex [19,30]. 
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Interestingly, human α-LA is not the only variant of the protein able to form cytotoxic 
complexes with OA. Alpha-lactalbumin of bovine, equine, caprine, and porcine origin also 
have the ability to form complexes with OA, showing HAMLET-like cytotoxicity, while 
natural HAMLET formation in acid precipitates of casein was unique to human milk [9]. 
Comparison of highly purified human and bovine α-LA´s ability to form complexes with 
OA showed that the two proteins behaved very similarly and that the cytotoxic activity was 
comparable [53]. 
The revelations that neither native-state, apo-state nor otherwise partially unfolded α-LA 
alone shows significant cytotoxic activity, in addition to the above-mentioned findings, have 
caused researchers to focus on the possibility that the cytotoxic component of HAMLET 
may be the fatty acid and not the α-LA protein [3,5,19,50]. As a consequence, it has been 
suggested that α-LA is merely a carrier or synergist of the tumor-killing activity of the 
associated oleic acid [48,49]. In agreement with this, studies have found that the cytotoxicity 
of OA alone is very similar to that of BAMLET, the bovine ortholog of HAMLET, and that of 
HAMLET-like complexes composed of bovine β-lactoglobulin and pike parvalbumin in 
complex with OA [40,54]. The cytotoxic activity of the β-lactoglobulin and paralbumin 
complexes even exceeded that of HAMLET, indicating that the proteinaceous component of 
the complexes is of less importance than the OA component in relation to the cytotoxic 
activity [40]. The potent toxicity of free oleic acid against Jurkat and HL-60 tumor cells has 
been shown, supporting the proposal that the fatty acid could be the cytotoxic component of 
the HAMLET complex [54,55]. However, in contrast with this proposal, α-LA has previously 
been found to be cytotoxic in the absence of oleic acid [56-60]. 
9. Stoichiometry of the protein and fatty acid in HAMLET and HAMLET-
like complexes 
The stoichiometry of protein and fatty acid in HAMLET or HAMLET-like complexes 
remains a topic of debate. Initial gas chromatography and mass spectrometry data 
suggested that the average number of oleic acid molecules bound in the HAMLET 
complex was 0.9, with some batch variation [6]. The assumption of a 1:1 protein/fatty acid 
ratio was also reported in the preparation of BAMLET by chromatography [61]. By gas 
chromatography and mass spectrometry a later study estimated an α-LA to OA ratio of 
1:5.4 in a HAMLET complex prepared by the OA-preconditioned anion exchange 
chromatography method [38]. An α-LA to OA ratio of 1:8.2 in HAMLET determined by 
LC-MS has also been reported [52]. A ratio of 1:10-1:13 was found for BAMLET and 
HAMLET complexes formed by a new alternative preparation method, using two 
consecutive DEAE-Sepharose ion exchange columns for the purification of α-LA and 
subsequent complex formation, but high variation in stoichiometry was common within 
different batches [53]. 
The average number of oleic acid molecules bound per α-LA in LA/OA complexes has been 
spectrofluorimetrically estimated to be 2.9 for LA/OA formed at 17°C and 9 for LA/OA 
formed at 45°C [30]. Another study has reported that the bovine LA/OA complex, prepared 
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by direct mixing of the constituents, consists of 4-5 protein molecules with 68-85 bound 
molecules of OA, thus indicating that every α-LA binds on average 17 OA molecules [49]. 
A possible explanation for the variation in the observed α-LA to OA ratios might be that the 
different preparation techniques and experimental conditions (e.g. changes in temperature 
or altered α-LA to OA ratios) could have a major impact on the observed stoichiometry. In 
addition, it has been proposed that some of the OA might be present in an unbound form 
resulting in a higher OA to α-LA ratio [30]. 
10. Methods of HAMLET or HAMLET-analog preparation in vitro 
Several different methods have been utilized for the in vitro preparation of HAMLET or its 
orthologs from α-LA and OA. These include OA-conditioned anion exchange 
chromatography using either a DEAE-Trisacryl M in the conventional method [3,5,6,19] or a 
DEAE-Sepharose column in an alternative method [53]. Direct mixing under heat 
denaturation [30,36,52], heat denaturation of α-LA and OA-conditioned anion exchange 
chromatography [62], direct mixing in solution at room temperature with alternated pH 
conditions [45,48,49,63], direct mixing followed by anion exchange chromatography [61] and 
alkaline conditions [64] have also been used. 
The conventional method of HAMLET preparation is OA-preconditioned anion exchange 
chromatography [5]. This method is initiated with the purification of native-state α-LA by 
hydrophobic interaction chromatography and subsequent EDTA-treatment, resulting in the 
loss of Ca2+ and partial unfolding of the protein. The apo-state α-LA is subjected to a DEAE- 
Trisacryl M ion exchange chromatographic column previously exposed to human milk or 
pre-loaded with fatty acids. The apo-state α-LA interacts with the OA pre-loaded column, 
forming the HAMLET complex, which elutes at a salt concentration of 1M. The eluted 
complex is desalted by dialysis and lyophilized to obtain HAMLET dry powder. 
Regardless of the preparation method used in the different experiments, it has been shown 
that the cytotoxicity of the resulting complexes was similar to that of conventionally 
prepared HAMLET or BAMLET [30,36,48,49,54,61-65]. 
11. Cellular trafficking of HAMLET 
In order to clarify the subcellular localization of HAMLET and the interactions of the 
complex with different tumor cell compartments, researchers have used biotinylated [5,66], 
I125 radioactive labeled [66,67] and Alexa Fluor 568-labeled HAMLET complexes in confocal 
microscopy and subcellular fractionation experiments [67-69]. Site-specific labeling of 
HAMLET and HAMLET-like complexes with aminooxy-Alexa Fluor 488 or biotin molecules 
has also been used [52]. 
It has previously been described that α-LA interacts with cell membranes and lipid bilayers, 
as well as fatty acids [41,70-74]. In addition, it has been observed that α-LA is able to rapidly 
insert itself into the lipid bilayer at pH 2 [75]. However, native human α-LA is only 
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inefficiently bound to and internalized by tumor cells, and does not translocate to the 
nucleus, nor influence tumor cell viability [3,5,68,69,76]. Even partial unfolding of human α-
LA has been shown to be insufficient for increased protein internalization into tumor cells 
[38]. In addition, human α-LA and oleic acid alone were unable to alter membrane 
structures, further indicating the necessity of interaction between unfolded α-LA and an 
associated fatty acid for efficient internalization of the HAMLET complex in tumor cells [76]. 
Even though a number of studies have focused on investigating the mechanism of HAMLET 
uptake by tumor cells, it still remains unclear. HAMLET has been shown to interact with the 
cell surface of tumor cells, be internalized and subsequently accumulate in the nucleus 
[3,5,67,68]. In the case of healthy cells, HAMLET interacted with the cell membrane and was 
internalized, but did not accumulate in the nuclei of the cells [4,67]. 
A study of the interaction between HAMLET and natural or artificially generated, 
negatively charged, model lipid membranes has revealed that the interaction results in loss 
of cell membrane integrity, leakage of vesicular contents and morphological changes of the 
membranes [76]. Interestingly, HAMLET disturbs the integrity of the tested membranes, 
even under physiological conditions, as opposed to native-state α-LA that only disrupts 
liposomes at acidic pH [77]. Similarly, at physiological conditions HAMLET readily distorts 
lipid monolayers at low concentrations, while forming pore-like oligomeric structures 
resembling annular oligomers at higher concentrations [78]. The ability to form oligomers is 
suggested to be a property of the α-LA polypeptide chain, enhanced by the fatty acid 
component, which might be important for the cytotoxic activity of HAMLET [78]. It has 
been suggested that the degree to which HAMLET and other LA-OA-complexes are able to 
disturb the membrane integrity, depends on the lipid composition and physical 
characteristics of the membrane [74,76]. 
HAMLET binds to the cell surface of intact tumor cells in a patchy distribution, indicating 
the possible targeting (e.g. receptor-binding) of the complex to specific membrane regions 
[76]. Another study found that HAMLET and an α-LA/OA complex formed at 17°C, 
interacts with and alters trans-membrane integral currents of artificial vesicles and natural 
plasma membranes of the green alga C. coralline [65]. The binding of the OA-complexes 
caused suppression of Ca2+ current and Ca2+-activated Cl- current, as well as increased 
nonspecific K+ leakage, indicating nonselective permeability of the depolarized plasma 
membrane [65]. Furthermore, all the OA-bound states of α-LA had a higher affinity for 
interaction with the membranes compared to α-LA alone, indicating a Ca2+-independent 
association. Similar results were obtained regarding the bactericidal activity and membrane 
depolarization effect of HAMLET, bovine β-lactoglobulin and pike parvalbumin in complex 
with OA on S. pneumococci bacteria [40,64]. Accordingly, it has been proposed that once the 
complex has adsorbed to the plasma membrane, it is most likely internalized by nonspecific 
pinocytosis, while other mechanisms of endocytosis, such as receptor-mediated endocytosis 
have not been ruled out [65]. 
Translocation of HAMLET from the membrane to the cytoplasm has been followed by 
confocal microscopy, showing the formation of intracellular aggregates in both normal cells 
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and in tumor cells, although accumulation of HAMLET was higher in tumor cells [4]. The 
mechanism of HAMLET redistribution from the cytoplasm to different organelles of the cell, 
especially the nucleus, remains to be clarified. Initial studies found that the nuclear uptake 
of α-LA/OA occurred through the nuclear pore complex in a Ca2+-independent manner, and 
that the accumulation of α-LA in the nucleus resulted in Ca2+-dependent DNA 
fragmentation in the tumor cells [66]. Later, it was suggested that the interaction between 
HAMLET and ribosomal proteins could initiate nuclear translocation and targeting of the 
complex [2]. 
12. Tumor cell death mechanisms of HAMLET 
A key unresolved issue regarding HAMLET is by what biological mechanisms the complex 
induces tumor cell death. A broad variety of transformed and immature tumor cells, but not 
healthy differentiated cells, have been found to be affected by the complex and even 
antibiotic-resistant strains of S. pneumoniae bacteria seem to be prone to the cytotoxic 
activity, showing apoptosis-like morphological and mechanistic changes [4,79,80]. HAMLET 
is believed to have multiple intracellular targets and has metaphorically been called a 
“Lernaean Hydra”, a mythological creature that uses numerous heads to attack enemies 
[51]. It has been shown that HAMLET induces at least three major responses, namely an 
apoptotic pathway, an autophagic pathway and chromatin structure disorder [1,67,81]. All 
the suggested tumor cell death mechanisms of HAMLET or HAMLET-like complexes are 
listed in Table 1. 
Besides the three major responses, it has been shown that BAMLET activates a caspase-
independent lysosomal cell death pathway mainly in tumor cells, causing lysosomal 
membrane permeabilization possibly contributing to BAMLET-induced cell death [61]. In a 
study of HAMLET binding to α-actinin, it has been indicated that the apoptosis-promoting 
p38 pathway is the top-scoring pathway in HAMLET-induced cell death, with p38 
inhibition delaying death of HAMLET-treated tumor cells [82]. 
An elevated expression level of c-Myc, an oncogene that has the ability to bind a significant 
fraction of all known gene promoters, has been shown to increase HAMLET-sensitivity of 
various tumor cells, suggesting that the level of c-Myc expression could be a direct 
determinant of HAMLET susceptibility [83]. Furthermore, a reduction in the extracellular 
glucose levels or degree of glycolysis, predominantly the aerobic glycolysis of tumor cells 
known as the Warburg Effect, of A549 lung carcinoma cells resulted in an enhanced 
HAMLET-sensitivity [83]. HAMLET was shown to bind and reduce the activity of the 
glycolytic enzyme hexokinase 1 in the A549 carcinoma cells, which could partly explain the 
inhibitory effect of HAMLET on glycolysis [83]. 
HAMLET has been shown to interact directly with 20S proteasome subunits in vitro as well 
as in vivo, resulting in structural modifications and partial inhibition of 20S proteasome 
activity, possibly leading to accumulation of incorrectly folded proteins contributing to cell 
death [69]. Moreover, HAMLET was found by N-terminal sequencing and MALDI-TOF-MS 
to bind intact ribosomes, as well as individual ribosomal proteins L4, L6, L15, L13a, L30, 
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L35a, S12 and L21 [2]. The plausible effects of the interaction are protein translational 
blocking and ribosome-initiated nuclear targeting of HAMLET [2].  
 
Responses Effects
Major responses: 
 
Apoptotic pathway [2,54,84,87,90,91] 
 
 
 
 
 
 
 
Autophagic pathway [81,91] 
 
 
Chomatin structure disorder [67,90,100] 
 
 
 
 
 
 
Other responses: 
 
Anti-adhesion [1,82,102]  
 
c-Myc oncogene status [83]  
 
  
Inhibition of 20S proteasome activity [69] 
 
 
Inhibition of glycolysis [83]  
 
Lysosomal pathway [61] 
 
 
 
p38 pathway [82] 
 
 
Ribosome interactions [2] 
 
 
MAL co-localizes with mitochondria and causes release 
of cytochrome c from the IMM to the cytosol 
MAL causes loss of mitochondrial membrane potential 
(ΔΨm) and abnormal MPT 
HAMLET causes p53-independent apoptotic or 
apoptotic-like cell death in tumor cells 
BAMLET-induced cell death varies according to cell type 
 
HAMLET induces an macroautophagic response in 
tumor cells 
 
HAMLET accumulates in the nucleus of tumor cells 
HAMLET binds to histones, independent of the histone 
tail, resulting in chromatin structure disorder in tumor 
cells 
HAMLET causes caspase-dependent and caspase-
independent chromatin condensation and acts in 
synergy with histone deacetylase inhibitors 
 
 
MAL and HAMLET facilitates tumor cell detachment 
 
Elevated expression of c-Myc oncogene sensitizes tumor 
cells to HAMLET-induced tumor cell death 
 
HAMLET binds to 20S proteasome subunits causing 
structural modifications and partial activity inhibition 
 
HAMLET binds to and reduces the activity of HK1 
 
BAMLET activates a caspase-independent lysosomal 
pathway in tumor cells leading to lysosomal membrane 
permeabilization 
 
Indicated to be the top-scoring cell death pathway of 
HAMLET 
 
HAMLET binds to intact ribosomes and individual 
ribosome proteins 
Table 1. The tumor cell death mechanisms of HAMLET and HAMLET-like complexes.  
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For elaboration of the specific tumor cells prone to the mentioned effect, the reader is 
encouraged to see the references. HK1, hexokinase 1; IMM, inner mitochondrial membrane; 
MAL, multimeric α-lactalbumin; MPT, mitochondrial permeability transition.  
13. HAMLET and apoptosis 
Several studies have focused on clarifying the precise role of apoptosis in the HAMLET-
induced cell death of tumor cells. Initially, it was shown by the use of an anti-CD95 antibody 
that the CD95 receptor-mediated apoptotic pathway had no effect on the apoptosis-inducing 
activity of MAL [84]. It was also found that MAL co-localized with mitochondria and caused 
release of cytochrome c from the inner mitochondrial membrane space to the cytosol, 
resulting in activation of caspase-3-like enzymes and, to a lesser degree, caspase-6-like 
enzymes of the caspase cascade [84]. The activation of cytosolic caspases by apogenetic 
factors released from the inner mitochondrial membrane (e.g. cytochrome c), and 
subsequent Apaf-1, procaspase-9 and dATP association, resulting in formation of the 
apoptosome complex, are normal events of the classical apoptotic pathway [85-87]. It was 
later revealed that MAL induced a loss of the mitochondrial membrane potential (ΔΨm) and 
abnormal mitochondrial permeability transition (MPT) in isolated mitochondria through 
opening of the MPT pore, resulting in Ca2+-dependent release of cytochrome c to the cytosol 
[87]. 
HAMLET-treated Jurkat leukemia cells and A549 lung carcinoma tumor cells exhibited 
classical apoptotic changes, as well as apoptosis-like changes, such as proapoptotic caspase 
activation, phosphatidyl serine externalization, DNA fragmentation, apoptotic body 
formation and compacted chromatin condensation [88-90]. However, classical apoptosis was 
not the cause of death, as a pan-caspase inhibitor zVAD-fmk was unable to rescue 
HAMLET-treated cells from dying [84,90]. This was confirmed by the finding that 
HAMLET-induced cell death is independent of the anti-apoptotic Bcl-2 and Bcl-xL proteins 
in Jurkat leukemia, K562 promyelocytic leukaemia and FL5.12 murine prolymphocytic 
tumor cells, as over-expression of Bcl-2 failed to prevent cell death [90]. In addition, the 
tumoricidal activity of HAMLET is independent of the tumor suppressor protein p53, as 
there was no difference in HAMLET susceptibility of tumor cells with wild-type, deleted or 
mutated p53 gene [2,90,91]. Analyzing the effect of BAMLET on Jurkat and THP1 cells by 
flow cytometry indicated that the death of Jurkat cells looked more apoptotic than the death 
of THP1 cells which were more necrotic, showing that the actual mechanism of cell death 
apparently varies between different types of cells [53]. 
14. HAMLET and macroautophagy 
Autophagy has been a topic of comprehensive debate concerning its function as an 
alternative caspase-independent type II programmed cell death pathway, in addition to 
serving as a survival mechanism during cellular stresses [92-95]. Macroautophagy, the only 
autophagic response included in type II programmed cell death, is an adaptive stress 
response observed in cells exposed to cellular stresses (e.g. starvation), which triggers the 
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recycle of organelles and long-lived proteins as a nutritional source utilized to prolong cell 
survival [91,92, 96]. 
HAMLET induces a macroautophagic response in treated tumor cells, with the appearance 
of cytoplasmic vacuoles and double-membrane enclosed vesicles [81,91]. Furthermore, 
HAMLET was shown to alter the staining-pattern of LC3-GFP-transfected cells from 
uniform (LC3-I) to granular (LC3-II), reflecting the translocation of LC3 to autophagosomes 
during macroautophagy [81]. HAMLET also induced LC3-II accumulation, detected by a 
Western Blot, when lysosomal degradation was inhibited, which is a clear indicative of 
macroautophagy [81].  
The inhibition of macroautophagy in HAMLET-treated tumor cells by RNA interference of 
Beclin-1 synthesis resulted in reduced cell death and inhibition of the increase in granular 
LC3-GFP staining, suggesting that macroautophagy is an important response pathway in 
HAMLET-induced cell death [81,91]. In accordance with this finding, it was shown that 
mTOR, an inhibitor of macroautophagy, is inactivated in tumor cells in response to 
HAMLET [81,97]. An important note is that the mitochondrial damage observed in the 
different tumor cells of the mentioned experiments also has the potential to trigger 
macroautophagy in the cells [81,98,99]. 
15. HAMLET cell nuclei interactions 
A striking feature of HAMLET is the ability to move through the cytoplasm and accumulate 
in the nucleus of tumor cells, as initially elucidated by the study of the active human milk 
fraction [3,66]. Healthy, differentiated cells did not accumulate biotinylated MAL or Alexa-
labeled HAMLET in the nucleus, although uptake in the cytoplasm was observed [66,67]. 
Through combination of in vitro and in vivo experiments, HAMLET was found to co-localize 
with histones and bind strongly to histone H3, as well as histones H4 and H2B to a lesser 
degree, resulting in perturbation of the chromatin structure and chromatin assembly in 
tumor cells, possibly impairing transcription, replication and recombination [67,100]. The 
binding of HAMLET to the histones was independent of the histone tail, and the binding 
impairs histone deposition on DNA. 
In a different study it has also been shown that monomeric Ca2+-loaded α-LA and apo-state 
α-LA alone can bind histone H3 in vitro, possibly through electrostatic interactions with 
several α-LA molecules bound per histone protein [101]. However, the finding should have 
no major implications on HAMLET studies, as native monomeric α-LA is unable to reach 
the cell nuclei of intact tumor cells [3,5,31]. 
HAMLET has been shown to act in synergy with histone deacetylase inhibitors, as pre-
treatment of Jurkat tumor cells with these resulted in enhanced lethal effect of HAMLET 
and an increased hyperacetylation response [100]. Caspase-independent DNA damage and 
DNA fragmentation was observed after treatment, suggesting that apoptosis was not the 
key pathway involved in the combined effect [100]. In addition, HAMLET caused chromatin 
condensation, as HAMLET-treatment of stably transfected HeLa cells resulted in a decrease 
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of nuclear size. The ability of HAMLET to induce both caspase-dependent and caspase-
independent chromatin condensation pattern was found in another study, indicating that 
the response to HAMLET involves both classical apoptosis and caspase-independent cell 
death pathways [90]. 
16. Anti-adhesive properties of HAMLET 
The ability of HAMLET to facilitate tumor cell detachment has been described both in early 
and recent literature. Initially, MAL was found to possess anti-adhesive properties against 
bacterial attachment to alveolar type II lung carcinoma cells [1]. Subsequently, an in vivo 
experiment studying the therapeutic effects of HAMLET on bladder cancer showed that 
HAMLET triggers massive shedding of dead tumor cells into the urine, further indicating 
the anti-adhesive properties of HAMLET towards tumor cells [102]. Later, in vitro studies 
revealed that HAMLET binds to α-actinin-4, in addition to interacting with α-actinin-1, and 
causes detachment of A549 lung carcinoma cells [82]. Furthermore, a reduction in β1 
integrin staining, as well as in FAK and ERK1/2 phosphorylation was observed, suggesting 
that HAMLET-treatment induced disruption of integrin-dependent cell adhesion signaling.  
17. Therapeutic applications of HAMLET 
A major reason for studying the cytotoxic activity of HAMLET is the apparent specificity 
towards cancer cells. Although this specificity of cytotoxic HAMLET-induced cell death 
remains unclear, there have been continuous indications in many in vitro studies that 
HAMLET could have a therapeutic potential. As a consequence, researchers started 
conducting in vivo studies of the possible applications of HAMLET [68,102-105]. The 
proposed therapeutic applications of HAMLET and the observed effects are listed in Table 2. 
One problem in using HAMLET as a potential cancer agent is its interaction with albumin, 
which through binding of free fatty acids could neutralize the cytotoxic activity of HAMLET 
or BAMLET [53,87,102]. As albumin is present in nearly all physiologic fluids, it will in 
many cases be difficult for HAMLET to reach the target cancer cells in an active form. 
The observed effects mentioned are in vivo unless otherwise noted. GBM: glioblastoma 
multiforme. 
18. HAMLET as a skin papilloma treatment 
Papillomas are characterized as premalignant lesions of the skin and mucosal surfaces, 
caused by human papillomavirus transformation of keratinocytes [4,104]. The therapeutic 
treatment options are ineffective and include cryotherapy, immuno modulators, curettage, 
cautery, salicylic acid, CO2 laser, antimitotic agents, or photo-dynamic theraphy [106,107]. 
Skin papillomas were the first model selected for the examination of the in vivo effects of 
HAMLET [104]. Patients resistant to conventional treatments were included in this 
randomized, placebo-controlled, double-blinded study. HAMLET was shown to reduce the 
papilloma volume in 100% (20/20) of the patients and 96% of their lesions (88/92), compared 
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to 15% in the placebo group patients (3/20) and 20% (15/74) of their lesions. By studying the 
long-term effects of HAMLET-treatment against skin papillomas, it was found that all 
lesions had completely resolved in 83% of the patients after 2 years. Furthermore, there were 
no observed differences between immunocompetent and immunosuppressed patients, 
indicating the potential of HAMLET-treatment for immunosuppressed skin papilloma 
patients, instead of the currently used invasive methods [104]. 
 
Applications Effects
Bladder cancer treatment [2,102,105] 
 
 
 
 
 
 
Gliblastoma (multiforme) treatment in a rat 
model [68] 
 
 
 
Skin papilloma treatment [104] 
Induces bladder carcinoma cell death (in vitro) 
Increases daily shedding of dead tumor cells into 
the urine 
Reduces tumor size or area and changes tumor 
character 
Delays progression of bladder cancer 
 
Induces apoptosis in GBM biopsy spheroids (in 
vitro) 
Reduces intracranial tumor volume 
Delays onset of pressure symptoms 
 
Reduces the volume of papillomas 
Leads to long-term resolution of lesions 
Similar effects of treatment in immunosuppressed 
patients as in immunocompetent patients 
Table 2. Possible therapeutic applications of HAMLET. 
19. HAMLET as a bladder cancer treatment 
The development of bladder cancers is common and remains a massive worldwide 
challenge, despite continuous advances in the therapeutic options available. The prevalence 
of bladder cancer is 1 in 4000 people, accounting for about 5% of all cancers, making it the 
fourth most common malignancy in the United States and the fifth most common in Europe 
[108]. The current treatments of bladder cancer typically involve intravesical instillation of 
antitumor agents such as Bacillus Calmette-Guerin, thiotepa, epirubicin and mitomycin C 
[109]. 
Early in vitro studies found that HAMLET induced rapid cell death in numerous cell lines, 
including bladder carcinoma cells [2]. The direct in vivo effect of HAMLET on bladder 
cancers was initially shown, when 9 male superficial bladder cancer patients received 
intravesical HAMLET-treatment during the week before scheduled transurethral surgery 
[102]. HAMLET stimulated a rapid increase in the daily shedding of dead tumor cells into 
the urine in 8 of 9 patients and an apoptotic response was detected by the TUNEL DNA 
fragmentation assay in 6 of 9 patients. In addition, a reduction in tumor size or a change in 
tumor character was observed at surgery in 8 of 9 patients. 
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The therapeutic potential of HAMLET was further studied in a mouse bladder carcinoma 
model, with MB49 carcinoma cells installed via a catheter into the bladder of anesthetized 
mice, followed by five intravesical installations of HAMLET [105]. The treatment resulted in 
significantly decreased tumor areas and delayed the progression of bladder cancer 
compared to controls. Furthermore, whole body imaging of Alexa Fluor 568-labeled 
HAMLET revealed that the uptake and retention of the complex were tumor tissue-specific. 
20. HAMLET in treatment of glioblastoma  
Gliomas are a heterogeneous group of intracranial neoplasms originating from neuroglial 
cells, which accounts for over 60% of all primary brain tumors and have an unfavorable 
prognosis [110-113]. Glioblastoma multiforme (GBM), grade IV on the current WHO 
grading-scale for tumors in the central nervous system, is the most malignant of the gliomas, 
showing a mean survival time of less than a year [113,114]. The current treatment is only 
palliative, involving surgery, radiotherapy and chemotherapy [115]. 
HAMLET has been shown to induce apoptosis in GBM biopsy spheroids in vitro, as detected 
by the TUNEL DNA fragmentation assay [68]. Similarly, in vivo studies of the effect of 
HAMLET-treatment on GBM’s, established by xenotransplantation of human glioblastoma 
biopsy spheroids into nude rat brains, showed that HAMLET reduced the intracranial 
tumor volume and delayed the onset of pressure symptoms in tumor-xenografted rats 
[68,116]. 
21. HAMLET and involution of the mammary gland 
The development of the mammary gland through puberty, pregnancy and lactation has 
been intensively studied and much is known about the factors responsible for regulating the 
processes. When suckling stops, the gland goes into involution, and despite much research 
little is known regarding the factors involved in this remodeling of the gland. 
Milk synthesis occurs in mammary epithelial organized in small hollow “balls” called 
alveoli. It is known that the accumulation of milk in the alveoli results in down regulation of 
protein synthesis as well as reduction in the number of secretory cells by apoptosis [117]. It 
is also believed that local factors secreted into the milk are responsible for the effect, but 
molecular details of such compounds are lacking. A protein called FIL (Feedback Inhibitor 
of Lactation) from milk has been isolated and partly characterized [118], but at present its 
existence is unconfirmed. 
Some sea animals have a special lactation cycle due to long periods of foraging trips away 
from the offspring. Remarkably, despite the absence of suckling for many days no apoptosis 
occurs in the mammary gland of e.g. Cape fur seals, and this phenotype has been correlated 
with lack of α-LA in their milk [119]. The possibility that α-LA either alone or in a complex 
with fatty acids is involved in the regulation of involution has been suggested as apoptotic 
cell death in the mammary gland was enhanced by the introducing of HAMLET in the 
gland of lactating mice [103]. 
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22. Conclusion 
The milk protein alpha-lactalbumin (α-LA) is one of the most studied proteins with respect 
to structure and function and has been a model for investigating intermediate folding 
conformations generally called molten globule states. It has a well-described function as part 
of the enzyme lactose synthetase, where α-LA is one component of the two-polypeptide 
enzyme. The other part is a non-specific galactosyl transferase, which in complex with α-LA 
becomes highly specific for forming lactose from UDP-galactose and glucose. 
In the late nineties an entirely different activity of α-LA was discovered. When α-LA is in a partly 
unfolded conformation it can form a complex with oleic acid (OA) where the complex shows 
cell-killing activity specific for cancer cells. This partly unfolded conformation of α-LA can be 
obtained by removing a tightly bound calcium ion, leaving the protein in the apo-state capable of 
interacting directly with OA and thereby forming the cytotoxic complex. The complex between 
human α-LA and OA has been called HAMLET (Human Alpha-lactalbumin Made LEthal to 
Tumor cells) and similar complexes can be formed with α-LA from other species.  
In cell culture systems HAMLET shows cytotoxic activity in µM concentrations but the 
activity varies greatly between cell types. The exact mechanism of cell-killing is not clear, 
but HAMLET has been shown to interact with numerous cell organelles including the 
nucleus, lysozymes, mitochondria, proteasomes and ribosomes. Apoptosis, autophagy and 
chromatin structure disorder are three different cytotoxic pathways described when 
HAMLET is added to cell cultures. It is therefore likely that different cells will show 
different death mechanisms dependent on the experimental conditions. 
When the cytotoxic activity of α-LA/OA complexes are measured in a dose-response 
manner, it is characteristic that very steep curves are obtained where as little as a four-fold 
dilution can result in no activity compared to 100% cell death in the undiluted solution. This 
underlines the importance of defining the experimental conditions exactly when measuring 
cytotoxic activity as small changes in concentration might lead to contradictory conclusions. 
This aspect is especially important when the activity of HAMLET is compared between 
healthy differentiated normal cells and tumor cells. According to numerous reports 
HAMLET kills tumor cells as well as undifferentiated cells but leave normal cells 
untouched. This has recently been questioned as it was found that both normal white blood 
cells and fully developed erythrocytes were highly sensitive to the cell-killing activity. 
The potential of HAMLET as a therapeutic agent has been investigated in three different 
models. First, skin papillomas were treated in a double-blinded study showing positive 
results compared to the controls, secondly, patients with bladder cancer indicated reduction 
in tumor size when the bladder was flushed with a solution of HAMLET, and finally, in a 
glioblastoma rat model HAMLET treatment resulted in a decrease of the intracranial tumor 
volume. This suggests that tumor cells in some cases might be more sensitive to HAMLET 
when compared with the healthy cells from which the tumors originate. 
It has been theorized that HAMLET could be naturally formed in the digestive system of 
breast-fed children, due to low pH conditions of the stomach, serving the function as a 
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natural scavenger and selective cytotoxic killer of cancerous cells in early infancy. The 
development of normal epithelia cells in the digestive system could also be affected. 
Obviously, many dairy products contains α-LA in fairly high concentrations and numerous 
production techniques, such as acid pH and heat treatment, facilitate the formation of partly 
unfolded α-LA making the protein ready to bind fatty acids and other similar compounds. 
To what degree such complexes in fact are formed in dairy products remains to be seen. 
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